P53- and mevalonate pathway-driven malignancies require Arf6 for metastasis and drug resistance

Journal of Cell Biology

Volumn 213, Issue 1, 2016, Pages 81-95

  Hashimoto, Ari ^a   Oikawa, Tsukasa ^a   Hashimoto, Shigeru ^a   Sugino, Hirokazu ^a   Yoshikawa, Ayumu ^a   Otsuka, Yutaro ^a   Handa, Haruka ^a   Onodera, Yasuhito ^a   Nam, Jin Min ^b   Oneyama, Chitose ^c   Okada, Masato ^c   Fukuda, Mitsunori ^d   Sabe, Hisataka ^a  

^a Graduate School of Medicine   (Japan)

^b HOKKAIDO UNIVERSITY   (Japan)

^c OSAKA UNIVERSITY   (Japan)

^d TOHOKU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE RIBOSYLATION FACTOR 6; F ACTIN; GEMCITABINE; GERANYLGERANYL TRANSFERASE II; MEVALONIC ACID; MUTANT PROTEIN; PROTEIN P53; PROTEIN TYROSINE KINASE; RAB11 PROTEIN; RAB11B PROTEIN; SCATTER FACTOR RECEPTOR; SIMVASTATIN; SMALL INTERFERING RNA; STEROL REGULATORY ELEMENT BINDING PROTEIN; TEMSIROLIMUS; TRANSFERASE; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; ADENOSINE DIPHOSPHATE RIBOSYLATION FACTOR; ADP-RIBOSYLATION FACTOR 6; ANTINEOPLASTIC AGENT; GAMMA GLUTAMYLTRANSFERASE; RAB PROTEIN; TP53 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER RESISTANCE; CANCER SURVIVAL; CARCINOGENESIS; CELL INVASION; CELL MEMBRANE; CELL MIGRATION; CELL VIABILITY; CELLULAR DISTRIBUTION; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; ENZYME ACTIVATION; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HUMAN; HUMAN CELL; LIPID RAFT; LUNG METASTASIS; MALIGNANT NEOPLASTIC DISEASE; MCF 7 CELL LINE; METABOLIC MEVALONATE PATHWAY; METASTASIS; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN PRENYLATION; SIGNAL TRANSDUCTION; TUMOR INVASION; CELL LINE; CELL MOTION; DRUG RESISTANCE; HEK293 CELL LINE; MCF-7 CELL LINE; METABOLISM; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ADP-RIBOSYLATION FACTORS; ANTINEOPLASTIC AGENTS; CELL LINE; CELL LINE, TUMOR; CELL MOVEMENT; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; GAMMA-GLUTAMYLTRANSFERASE; HEK293 CELLS; HUMANS; MCF-7 CELLS; MEVALONIC ACID; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; RAB GTP-BINDING PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84964994848     PISSN: 00219525     EISSN: 15408140     Source Type: Journal    
DOI: 10.1083/jcb.201510002     Document Type: Article

References (53)

1. Adorno, M., M. Cordenonsi, M. Montagner, S. Dupont, C. Wong, B. Hann, A. Solari, S. Bobisse, M.B. Rondina, V. Guzzardo, et al. 2009. A Mutant-p53/Smad complex opposes p63 to empower TGFβ-induced metastasis. Cell. 137:87-98. http ://dx .doi .org /10 .1016 /j .cell .2009 .01 .039
2. Akagi, T., K. Sasai, and H. Hanafusa. 2003. Refractory nature of normal human diploid fibroblasts with respect to oncogene-mediated transformation. Proc. Natl. Acad. Sci. USA. 100:13567-13572. http ://dx .doi .org /10 .1073 /pnas .1834876100
3. Altwairgi, A.K. 2015. Statins are potential anticancerous agents (review). Oncol. Rep. 33:1019-1039.
4. Berndt, N., A.D. Hamilton, and S.M. Sebti. 2011. Targeting protein prenylation for cancer therapy. Nat. Rev. Cancer. 11:775-791. http ://dx .doi .org /10.1038 /nrc3151
5. Cancer Genome Atlas Network. 2012. Comprehensive molecular portraits of human breast tumours. Nature. 490:61-70. http ://dx .doi .org /10 .1038 / nature11412
6. Coleman, M.P., M. Quaresma, F. Berrino, J.-M. Lutz, R. De Angelis, R. Capocaccia, P. Baili, B. Rachet, G. Gatta, T. Hakulinen, et al. CON CORD Working Group. 2008. Cancer survival in five continents: a worldwide population-based study (CON CORD). Lancet Oncol. 9:730-756. http ://dx .doi .org /10 .1016 /S1470 -2045(08)70179 -7
7. Coxon, F.P., F.H. Ebetino, E.H. Mules, M.C. Seabra, C.E. McKenna, and M.J. Rogers. 2005. Phosphonocarboxylate inhibitors of Rab geranylgeranyl transferase disrupt the prenylation and membrane localization of Rab proteins in osteoclasts in vitro and in vivo. Bone. 37:349-358. http ://dx .doi .org /10 .1016 /j .bone .2005 .04 .021
8. De Benedetti, A., and J.R. Graff. 2004. eIF-4E expression and its role in malignancies and metastases. Oncogene. 23:3189-3199. http ://dx .doi .org /10 .1038 /sj .onc .1207545
9. Duggan, D.E., I.W. Chen, W.F. Bayne, R.A. Halpin, C.A. Duncan, M.S. Schwartz, R.J. Stubbs, and S. Vickers. 1989. The physiological disposition of lovastatin. Drug Metab. Dispos. 17:166-173.
10. Elenbaas, B., L. Spirio, F. Koerner, M.D. Fleming, D.B. Zimonjic, J.L. Donaher, N.C. Popescu, W.C. Hahn, and R.A. Weinberg. 2001. Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. Genes Dev. 15:50-65. http ://dx .doi .org /10 .1101 /gad .828901
11. Elster, N., D.M. Collins, S. Toomey, J. Crown, A.J. Eustace, and B.T. Hennessy. 2015. HER2-family signalling mechanisms, clinical implications and targeting in breast cancer. Breast Cancer Res. Treat. 149:5-15. http ://dx .doi .org /10 .1007 /s10549 -014 -3250 -x
12. Endo, A., M. Kuroda, and Y. Tsujita. 1976. ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium. J. Antibiot. (Tokyo). 29:1346-1348. http ://dx .doi .org /10 .7164 /antibiotics .29 .1346
13. Faulds, M.H., C. Zhao, K. Dahlman-Wright, and J.-Å. Gustafsson. 2012. The diversity of sex steroid action: regulation of metabolism by estrogen signaling. J. Endocrinol. 212:3-12. http ://dx .doi .org /10 .1530 /JOE -11 -0044
14. Fischer, K.R., A. Durrans, S. Lee, J. Sheng, F. Li, S.T. Wong, H. Choi, T. El Rayes, S. Ryu, J. Troeger, et al. 2015. Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature. 527:472-476. http ://dx .doi .org /10 .1038 /nature15748
15. Freed-Pastor, W.A., H. Mizuno, X. Zhao, A. Langerød, S.-H. Moon, R. Rodriguez-Barrueco, A. Barsotti, A. Chicas, W. Li, A. Polotskaia, et al. 2012. Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell. 148:244-258. http ://dx .doi .org /10 .1016 /j .cell .2011 .12 .017
16. Frisch, S.M., M. Schaller, and B. Cieply. 2013. Mechanisms that link the oncogenic epithelial-mesenchymal transition to suppression of anoikis. J. Cell Sci. 126:21-29. http ://dx .doi .org /10 .1242 /jcs .120907
17. Goldstein, J.L., and M.S. Brown. 1990. Regulation of the mevalonate pathway. Nature. 343:425-430. http ://dx .doi .org /10 .1038 /343425a0
18. Grant, B.D., and J.G. Donaldson. 2009. Pathways and mechanisms of endocytic recycling. Nat. Rev. Mol. Cell Biol. 10:597-608. http ://dx .doi .org /10.1038 /nrm2755
19. Grunt, T.W., and G.L. Mariani. 2013. Novel approaches for molecular targeted therapy of breast cancer: interfering with PI3K/AKT/mTOR signaling. Curr. Cancer Drug Targets. 13:188-204. http ://dx .doi .org /10 .2174 /1568009611313020008
20. Hashimoto, A., S. Hashimoto, R. Ando, K. Noda, E. Ogawa, H. Kotani, M. Hirose, T. Menju, M. Morishige, T. Manabe, et al. 2011. GEP100-Arf6-AMAP1-cortactin pathway frequently used in cancer invasion is activated by VEG FR2 to promote angiogenesis. PLoS One. 6:e23359. http ://dx .doi .org /10 .1371 /journal .pone .0023359
21. Hashimoto, S., A. Hashimoto, A. Yamada, C. Kojima, H. Yamamoto, T. Tsutsumi, M. Higashi, A. Mizoguchi, R. Yagi, and H. Sabe. 2004b. A novel mode of action of an ArfGAP, AMAP2/PAG3/Papα, in Arf6 function. J. Biol. Chem. 279:37677-37684. http ://dx .doi .org /10 .1074 /jbc .M404196200
22. Hashimoto, S., Y. Onodera, A. Hashimoto, M. Tanaka, M. Hamaguchi, A. Yamada, and H. Sabe. 2004a. Requirement for Arf6 in breast cancer invasive activities. Proc. Natl. Acad. Sci. USA. 101:6647-6652. http ://dx .doi .org /10 .1073 /pnas .0401753101
23. Hashimoto, S., M. Hirose, A. Hashimoto, M. Morishige, A. Yamada, H. Hosaka, K. Akagi, E. Ogawa, C. Oneyama, T. Agatsuma, et al. 2006. Targeting AMAP1 and cortactin binding bearing an atypical src homology 3/ proline interface for prevention of breast cancer invasion and metastasis. Proc. Natl. Acad. Sci. USA. 103:7036-7041. http ://dx .doi .org /10 .1073 /pnas .0509166103
24. Hashimoto, S., S. Mikami, H. Sugino, A. Yoshikawa, A. Hashimoto, Y. Onodera, S. Furukawa, H. Handa, T. Oikawa, Y. Okada, et al. 2016. Lysophosphatidic acid activates Arf6 to promote the mesenchymal malignancy of renal cancer. Nat. Commun. 7:10656. http ://dx .doi .org /10.1038 /ncomms10656
25. Hirano, M., S. Hashimoto, S. Yonemura, H. Sabe, and S. Aizawa. 2008. EPB41L5 functions to post-transcriptionally regulate cadherin and integrin during epithelial-mesenchymal transition. J. Cell Biol. 182:1217-1230. http ://dx .doi .org /10 .1083 /jcb .200712086
26. Irwin, M.E., K.L. Mueller, N. Bohin, Y. Ge, and J.L. Boerner. 2011. Lipid raft localization of EGFR alters the response of cancer cells to the EGFR tyrosine kinase inhibitor gefitinib. J. Cell. Physiol. 226:2316-2328. http ://dx .doi .org /10 .1002 /jcp .22570
27. Jukema, J.W., C.P. Cannon, A.J. de Craen, R.G. Westendorp, and S. Trompet. 2012. The controversies of statin therapy: weighing the evidence. J. Am. Coll. Cardiol. 60:875-881. http ://dx .doi .org /10 .1016 /j .jacc .2012 .07 .007
28. Kinoshita, R., J.M. Nam, Y.M. Ito, K.C. Hatanaka, A. Hashimoto, H. Handa, Y. Otsuka, S. Hashimoto, Y. Onodera, M. Hosoda, et al. 2013. Cooverexpression of GEP100 and AMAP1 proteins correlates with rapid local recurrence after breast conservative therapy. PLoS One. 8:e76791. http ://dx .doi .org /10 .1371 /journal .pone .0076791
29. Li, Y.C., M.J. Park, S.K. Ye, C.W. Kim, and Y.N. Kim. 2006. Elevated levels of cholesterol-rich lipid rafts in cancer cells are correlated with apoptosis sensitivity induced by cholesterol-depleting agents. Am. J. Pathol. 168:1107-1118. http ://dx .doi .org /10 .2353 /ajpath .2006 .050959
30. Macdonald, J.L., and L.J. Pike. 2005. A simplified method for the preparation of detergent-free lipid rafts. J. Lipid Res. 46:1061-1067. http ://dx .doi .org /10 .1194 /jlr .D400041 -JLR200
31. Maring, J.G., H.J. Groen, F.M. Wachters, D.R. Uges, and E.G. de Vries. 2005. Genetic factors influencing pyrimidine-antagonist chemotherapy. Pharmacogenomics J. 5:226-243. http ://dx .doi .org /10 .1038 /sj .tpj .6500320
32. Matsui, T., T. Itoh, and M. Fukuda. 2011. Small GTPase Rab12 regulates constitutive degradation of transferrin receptor. Traffic. 12:1432-1443. http ://dx .doi .org /10 .1111 /j .1600 -0854 .2011 .01240 .x
33. Menju, T., S. Hashimoto, A. Hashimoto, Y. Otsuka, H. Handa, E. Ogawa, Y. Toda, H. Wada, H. Date, and H. Sabe. 2011. Engagement of overexpressed Her2 with GEP100 induces autonomous invasive activities and provides a biomarker for metastases of lung adenocarcinoma. PLoS One. 6:e25301. http ://dx .doi .org /10 .1371 /journal .pone .0025301
34. Moffat, J., D.A. Grueneberg, X. Yang, S.Y. Kim, A.M. Kloepfer, G. Hinkle, B. Piqani, T.M. Eisenhaure, B. Luo, J.K. Grenier, et al. 2006. A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell. 124:1283-1298. http ://dx .doi .org /10 .1016 /j .cell .2006 .01 .040
35. Morgenstern, J.P., and H. Land. 1990. Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res. 18:3587-3596. http ://dx .doi .org /10 .1093 /nar /18 .12 .3587
36. Morishige, M., S. Hashimoto, E. Ogawa, Y. Toda, H. Kotani, M. Hirose, S. Wei, A. Hashimoto, A. Yamada, H. Yano, et al. 2008. GEP100 links epidermal growth factor receptor signalling to Arf6 activation to induce breast cancer invasion. Nat. Cell Biol. 10:85-92. http ://dx .doi .org /10 .1038 /ncb1672
37. Nezasa, K., A. Takao, K. Kimura, M. Takaichi, K. Inazawa, and M. Koike. 2002. Pharmacokinetics and disposition of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in rat. Xenobiotica. 32:715-727. http ://dx .doi .org /10 .1080 /00498250210144820
38. Ocaña, A., E. Amir, B. Seruga, M. Martin, and A. Pandiella. 2013. The evolving landscape of protein kinases in breast cancer: clinical implications. Cancer Treat. Rev. 39:68-76. http ://dx .doi .org /10 .1016 /j .ctrv .2012 .05 .004
39. Onodera, Y., S. Hashimoto, A. Hashimoto, M. Morishige, Y. Mazaki, A. Yamada, E. Ogawa, M. Adachi, T. Sakurai, T. Manabe, et al. 2005. Expression of AMAP1, an ArfGAP, provides novel targets to inhibit breast cancer invasive activities. EMBO J. 24:963-973. http ://dx .doi .org /10 .1038 /sj .emboj .7600588
40. Onodera, Y., J.M. Nam, A. Hashimoto, J.C. Norman, H. Shirato, S. Hashimoto, and H. Sabe. 2012. Rab5c promotes AMAP1-PRKD2 complex formation to enhance β1 integrin recycling in EGF-induced cancer invasion. J. Cell Biol. 197:983-996. http ://dx .doi .org /10 .1083 /jcb .201201065
41. Sadeghi, M.M., M. Collinge, R. Pardi, and J.R. Bender. 2000. Simvastatin modulates cytokine-mediated endothelial cell adhesion molecule induction: involvement of an inhibitory G protein. J. Immunol. 165:2712-2718. http ://dx .doi .org /10 .4049 /jimmunol .165 .5 .2712
42. Sato, H., K.C. Hatanaka, Y. Hatanaka, H. Hatakeyama, A. Hashimoto, Y. Matsuno, S. Fukuda, and H. Sabe. 2014. High level expression of AMAP1 protein correlates with poor prognosis and survival after surgery of head and neck squamous cell carcinoma patients. Cell Commun. Signal. 12:17. http ://dx .doi .org /10 .1186 /1478 -811X -12 -17
43. Shibata, M.A., Y. Ito, J. Morimoto, and Y. Otsuki. 2004. Lovastatin inhibits tumor growth and lung metastasis in mouse mammary carcinoma model: a p53-independent mitochondrial-mediated apoptotic mechanism. Carcinogenesis. 25:1887-1898. http ://dx .doi .org /10 .1093 /carcin /bgh201
44. Stenmark, H. 2009. Rab GTPases as coordinators of vesicle traffic. Nat. Rev. Mol. Cell Biol. 10:513-525. http ://dx .doi .org /10 .1038 /nrm2728
45. Tryndyak, V.P., F.A. Beland, and I.P. Pogribny. 2010. E-cadherin transcriptional down-regulation by epigenetic and microRNA-200 family alterations is related to mesenchymal and drug-resistant phenotypes in human breast cancer cells. Int. J. Cancer. 126:2575-2583.
46. Uchiyama-Tanaka, Y., H. Matsubara, Y. Mori, A. Kosaki, N. Kishimoto, K. Amano, S. Higashiyama, and T. Iwasaka. 2002. Involvement of HBEGF and EGF receptor transactivation in TGF-β-mediated fibronectin expression in mesangial cells. Kidney Int. 62:799-808. http ://dx .doi .org /10 .1046 /j .1523 -1755 .2002 .00537 .x
47. Vickers, S., C.A. Duncan, I.W. Chen, A. Rosegay, and D.E. Duggan. 1990. Metabolic disposition studies on simvastatin, a cholesterol-lowering prodrug. Drug Metab. Dispos. 18:138-145.
48. Wasielewski, M., F. Elstrodt, J.G. Klijn, E.M. Berns, and M. Schutte. 2006. Thirteen new p53 gene mutants identified among 41 human breast cancer cell lines. Breast Cancer Res. Treat. 99:97-101. http ://dx .doi .org /10 .1007 /s10549 -006 -9186 -z
49. Wiemer, A.J., D.F. Wiemer, and R.J. Hohl. 2011. Geranylgeranyl diphosphate synthase: an emerging therapeutic target. Clin. Pharmacol. Ther. 90:804-812. http ://dx .doi .org /10 .1038 /clpt .2011 .215
50. Yeganeh, B., E. Wiechec, S.R. Ande, P. Sharma, A.R. Moghadam, M. Post, D.H. Freed, M. Hashemi, S. Shojaei, A.A. Zeki, and S. Ghavami. 2014. Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease. Pharmacol. Ther. 143:87-110. http ://dx .doi .org /10 .1016 /j .pharmthera .2014 .02 .007
51. Yu, M., A. Bardia, B.S. Wittner, S.L. Stott, M.E. Smas, D.T. Ting, S.J. Isakoff, J.C. Ciciliano, M.N. Wells, A.M. Shah, et al. 2013. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science. 339:580-584. http ://dx .doi .org /10 .1126 /science .1228522
52. Zheng, X., J.L. Carstens, J. Kim, M. Scheible, J. Kaye, H. Sugimoto, C.C. Wu, V.S. LeBleu, and R. Kalluri. 2015. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature. 527:525-530. http ://dx .doi .org /10 .1038 /nature16064
53. Zhou, X., E.J. Born, C. Allen, S.A. Holstein, and D.F. Wiemer. 2015. N-Oxide derivatives of 3-(3-pyridyl)-2-phosphonopropanoic acids as potential inhibitors of Rab geranylgeranylation. Bioorg. Med. Chem. Lett. 25:2331-2334. http ://dx .doi .org /10 .1016 /j .bmcl .2015 .04 .021